Drug intelligence / Profile preview

XH1

Development stage: Phase 2
Lead developer: Haining Health-Coming Biotech

Overview

XH1 is a Traditional Chinese Medicine (TCM) formulation developed by Haining Health-Coming Biotech for the treatment of advanced non-small cell lung cancer (NSCLC). It is primarily investigated as an adjunctive therapy to be administered alongside standard chemotherapy, specifically docetaxel, in patients with Stage IIIB-IV NSCLC who have failed first-line treatment. The clinical development of XH1 focuses on its potential to improve progression-free survival (PFS), overall survival (OS), and objective response rates, while also enhancing the quality of life for patients undergoing second-line chemotherapy. As a TCM product, its specific botanical composition and molecular mechanisms of action are not publicly detailed in clinical registries.

Other names: Chinese traditional medicine XH1Traditional Chinese Medicine XH1TCM XH1

Beyond the preview

Go deeper on XH1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XH1.

Explore the full profile